Ergomed joins Covid-19 therapy programme
By Josh White
Date: Monday 06 Apr 2020
(Sharecast News) - Specialised pharmaceutical services provider Ergomed announced on Monday that it is providing support for a clinical development programme for 'namilumab', a monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), for the treatment of patients with rapidly worsening Covid-19 coronavirus symptoms.
The AIM-traded firm said the programme was being conducted at the Humanitas Research Hospitals in Bergamo and Milan in Italy, and was supported by Izana Bioscience - an Oxford-based biopharmaceutical company focused on the development of namilumab.
It said it had been "integrally involved" in establishing the programme, drawing on its developing expertise in Covid-19, and the flexibility that underpinned its specialist capabilities, including its site management model in successfully managing complex clinical programmes.
"Research into potential treatments for Covid-19, and particularly the re-purposing of existing therapies and candidates, is imperative if the impact of the pandemic is to be reduced," said executive chairman Dr Miroslav Reljanović.
"We are currently providing clinical, operational and pharmacovigilance services to the re-purposing of three compounds for critically ill patients with Covid-19, demonstrating our ability to respond rapidly to customers' needs at this time.
"As our experience with Covid-19 continues to build, we hope to bring our capabilities and expertise increasingly to bear on this fast moving and critically important field."
At 1604 BST, shares in Ergomed were down 0.1% at 442.06p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN